
    
      The objective of this study is to gain tolerability and efficacy data for Norvir-boosted
      Lexiva versus Sustiva, both used in combination with Epzicom, as components of a first-line,
      once daily regimen for the treatment of HIV-1 infection in a patient population that is
      underrepresented in US clinical research.
    
  